Depressive disorder
Conditions
Interventions
Electroconvulsive therapy group:Electroconvulsive therapy
Sponsors
The Affiliated Brain Hospital, Guangzhou Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of major depressive disorder (MDD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5); 2. Baseline score >= 35 on the 24-item Hamilton Depression Rating Scale (HAMD-24); 3. All patients are first-time recipients of MST/ECT treatment, and their attending psychiatrists have clinically evaluated that the patients meet the indications for ECT, determined that the patients are scheduled to receive ECT treatment, and confirmed that the patients have the medical basis for receiving MST intervention; 4. Aged 18 to 65 years; 5. Signed the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Current or prior organic brain disease or neurological disorders; 2. Full-scale IQ < 70 on the Wechsler Abbreviated Scale of Intelligence; 3. Contraindication to anaesthesia, including known allergy to anaesthetic agents; 4. Concurrent use of anticonvulsants, benzodiazepines, or any other medication that may affect seizure threshold; 5. Prior exposure to ECT, MST, transcranial magnetic stimulation (TMS), transcranial direct-current stimulation (tDCS), transcranial alternating-current stimulation (tACS), or any other neurostimulation modality within the preceding 6 months; 6. Presence of cochlear implants, cardiac pacemakers, other implanted electronic devices, or intracranial ferromagnetic material; 7. Pregnancy or lactation; 8. Participation in another concurrent clinical trial; 9. Refusal to provide informed consent; 10. Any other condition judged by the investigators to render the participant unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 95% confidence interval for the difference between antidepressant relief rate and effective rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Side effect;Neurocognitive function; | — |
Countries
China
Contacts
Public ContactZheng Wei
The Affiliated Brain Hospital, Guangzhou Medical University
Outcome results
None listed